Keros Therapeutics adopts 'poison pill' plan
10/04/2025 11:07
April 10 (Reuters) - Keros Therapeutics KROS.O said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors. The company also said it had launched a process to evaluate strategic alternatives, including a possible sale of the company. (Reporting by Manas Mishra in Bengaluru; Editing by Shilpi Majumdar) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops